[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Praxis Precision Medicines Chief Financial Officer reports stock purchase under employee plan

The Chief Financial Officer of Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing the acquisition of company stock through the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan. On 11/14/2025, the officer acquired 384 shares of common stock at a price of $31.62 per share in a transaction reported as an acquisition. Following this transaction, the officer beneficially owns 24,663 shares of Praxis common stock directly. The filing notes that the purchase was made under an employee stock purchase plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c), which govern certain insider transactions for reporting and short-swing profit rules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Timothy Edwin

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		A(1)		384	A	$31.62	24,663	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

	/s/ Alex Nemiroff, as Attorney-in-Fact	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PRAX disclose in this Form 4?

The Form 4 reports that the Chief Financial Officer of Praxis Precision Medicines, Inc. (PRAX) acquired 384 shares of common stock on 11/14/2025 through the company’s Employee Stock Purchase Plan at a price of $31.62 per share.

How many PRAX shares does the reporting person own after this transaction?

After the reported transaction, the officer beneficially owns 24,663 shares of Praxis Precision Medicines common stock, held in direct ownership.

Who is the reporting person in this PRAX Form 4 and what is their role?

The reporting person is an officer of Praxis Precision Medicines, Inc. serving as the company’s Chief Financial Officer, as indicated in the filing.

Under what plan were the PRAX shares acquired in this filing?

The 384 shares reported were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan, as described in the Explanation of Responses section.

Were the PRAX insider transactions in this Form 4 exempt under SEC rules?

Yes. The filing states that the shares were acquired in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c), which relate to insider transactions under equity compensation or purchase plans.

Is this PRAX Form 4 filed by an individual or a group?

The filing indicates that it is a Form filed by one reporting person, not a joint or group filing.